AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amphastar Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.14+0.27 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Amphastar Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finished Pharmaceutical Products Segment | – | – | – | – | – | – | – | $720.48M | $705.63M | $666.10M | $630.27M | $587.96M | – | – |
| Active Pharmaceutical Ingredient Segment | – | – | – | – | – | – | – | $9.76M | $12.49M | $11.80M | $14.12M | $13.36M | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | – | – | $719.89M | $723.76M | $720.74M | $725.71M | $712.81M | $681.49M | $644.52M | $610.85M | $593.24M | $572.61M | – | – |
| Other | – | – | – | – | – | – | – | $42.06M | $68.37M | – | $51.16M | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $683.21M | $677.87M | $681.42M | $684.96M | $691.20M | $700.61M | $707.68M | $707.87M | $699.42M | $666.89M | $635.19M | $591.06M | 93.6% | -1.2% |
| France | $36.96M | $37.07M | $35.28M | $33.89M | $28.73M | $26.03M | $19.95M | $11.17M | $8.31M | $4.54M | $4.70M | $5.83M | 5.1% | +28.6% |
| China | $9.85M | $5.59M | $3.18M | $4.45M | $2.75M | $4.02M | $4.34M | $4.51M | $5.16M | $4.78M | $4.51M | $4.42M | 1.3% | +257.8% |
From the segment and revenue-disaggregation notes of Amphastar Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.